Medications are eliminated from the body primarily through two mechanisms: metabolism and excretion. The kidneys are responsible for eliminating most drugs from the body. Eliquis is cleared by both the kidneys and the liver, with approximately 27% of the drug excreted unchanged in the urine. This makes renal function an important, but not the sole factor, when determining appropriate dosing.
As with many medications, the dose of Eliquis needs to be adjusted in patients with compromised kidney function. The dose adjustment helps prevent the accumulation of Eliquis, which can raise the risk of bleeding in patients with impaired kidney function, especially in older adults or those with other comorbidities. Dose adjustments help strike a balance between clot prevention and safety. In this guide, we’ll break down how kidney function affects Eliquis dosing and what adjustments may be necessary to balance clot prevention with safety.
What is Eliquis and How Does It Work?
Eliquis (apixaban) is a prescription anticoagulant developed by Bristol-Myers Squibb, used to reduce the risk of blood clots and stroke. While commonly referred to as a blood thinner, it is technically classified as a factor Xa inhibitor. Approved by the FDA in 2012, Eliquis is part of a group of medications known as direct oral anticoagulants (DOACs), which also includes Xarelto (rivaroxaban), edoxaban, and dabigatran. Edoxaban and dabigatran were initially sold under the brand names Lixiana and Pradaxa, respectively, before those trademarks expired.
Hemostasis, the process of stopping or preventing bleeding, is highly complex and involves multiple pathways, cascades, and overlapping mechanisms that help the body seal injured blood vessels. One of these pathways relies on a substance called factor Xa, which circulates in the bloodstream and becomes active in response to injury. Factor Xa plays a key role by converting prothrombin into thrombin, which then converts fibrinogen into fibrin, a protein essential for blood clot formation. By blocking factor Xa, Eliquis disrupts this chain of events and helps prevent clot formation. For this reason, Eliquis and similar medications like Xarelto and edoxaban are known as factor Xa inhibitors.
What is Eliquis Used For?
Eliquis has earned FDA approval for several key uses tied to clot prevention:
- Protecting the brain: It helps lower the risk of stroke and systemic embolism in people with nonvalvular atrial fibrillation (a type of irregular heartbeat not caused by a heart valve problem).
- Safeguarding after surgery: It’s prescribed to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients recovering from hip or knee replacement surgery.
- Treating and preventing clots: Eliquis is used to treat DVT and PE, and to help prevent these clots from coming back after initial treatment.
Other Uses (Off-label uses)
Though not officially approved for these conditions, Eliquis may also be used off-label in certain situations, such as:
- Atrial flutter, another type of irregular heart rhythm
- Heparin-induced thrombocytopenia (HIT), although the use of Eliquis in this setting is not standard and requires specialist guidance
- Left ventricular thrombus, a clot that forms in the heart’s main pumping chamber
These off-label uses are typically guided by clinical judgment and emerging evidence.
Understanding Eliquis Dosage Options
Normal Dosage for Eliquis in Adults
The normal dosage for Eliquis in adults ranges from 2.5 to 10 mg twice daily, depending on the condition being treated. The standard dose of Eliquis for each indication varies slightly:
- Atrial fibrillation: 5 mg twice daily
- Treatment of venous thromboembolism (VTE, or blood clot): 10 mg twice daily for 7 days, then 5 mg twice daily
- Prevention of VTE after a knee or hip replacement: 2.5 mg twice daily
The length of therapy can be as short as 10-14 days when used to prevent blood clots after knee or hip replacement. However, for those with atrial fibrillation, it may be indefinite, depending on your clotting risk.
Comparing Eliquis Strengths and Formulations
Eliquis is available as an oral tablet in two different strengths: 2.5 mg and 5 mg. The 2.5 mg tablet is yellow while the 5 mg tablet is pink. The tablets are for oral administration only; however, they can be crushed and suspended in water, apple juice, or mixed with applesauce and administered orally or via a nasogastric (NG) tube if needed.
Eliquis Renal Dosing: When to Reduce the Dose
How Kidney Function Impacts Eliquis Levels
When the kidneys are functioning properly, they can process and eliminate Eliquis through the urine. In cases of chronic kidney disease (CKD) or acute kidney injury (AKI), the kidneys struggle to eliminate Eliquis, which leads to a buildup of the medication. A higher concentration of Eliquis in the body increases the risk of side effects. The most significant concern is the increased risk of bleeding, which can lead to death when left unaddressed.
When to Reduce the Eliquis Dose
Three factors are taken into consideration when deciding whether to reduce the dose of Eliquis due to reduced kidney function. The first is serum creatinine (SCr), which is an indicator of waste products in the kidneys. A higher serum creatinine level may indicate that the kidneys are not functioning properly. A normal SCr ranges from 0.6 to 1.3 mg/dL. The other two factors are age and body weight. There are two scenarios in which a reduced Eliquis dose would be recommended:
Scenario #1: The SCr is less than 1.5 mg/dl, but the patient is at least 80 years of age and has a body weight ? 60 kg (or 132 lbs)
Scenario #2: The SCr is equal to or above 1.5 mg/dl, and the patient is either at least 80 years of age or has a body weight ? 60 kg (or 132 lbs)
An Eliquis dose reduction is primarily used in nonvalvular atrial fibrillation and end-stage renal disease (ESRD) for patients with mild-to-moderate renal impairment. However, there are sometimes additional considerations in other patient populations with severe renal disease.
Eliquis Dosing by Indication and Kidney Function
| Indication | Standard Dose | Renal Function Considerations | Dose Adjustment |
| Nonvalvular Atrial Fibrillation (NVAF) | 5 mg twice daily | Assess for dose reduction if: age ?80, body weight ?60 kg, or serum creatinine ?1.5 mg/dL | Reduce to 2.5 mg twice daily if 2 of 3 criteria are met |
| DVT/PE Treatment | 10 mg twice daily for 7 days, then 5 mg twice daily | No dose adjustment needed for mild-to-moderate renal impairment | Use caution in severe renal impairment (CrCl <15 mL/min) or on dialysis (limited data) |
| DVT/PE Prevention After Initial Treatment | 2.5 mg twice daily after at least 6 months of treatment | Same as above | No dose adjustment unless severe renal dysfunction. Caution is advised |
| DVT/PE Prophylaxis After Hip or Knee Replacement | 2.5 mg twice daily starting 12–24 hours post-surgery | Same as above | No dose adjustment unless severe renal dysfunction. Caution is advised |
| End-Stage Renal Disease (ESRD) on Dialysis | 5 mg twice daily | Consider 2.5 mg twice daily if age ?80 or body weight ?60 kg | Not FDA-labeled for this use. Clinical judgment should be used. |
What Happens If You Miss a Dose of Eliquis?
Eliquis is prescribed to be taken twice daily, with a separation of approximately 12 hours between doses. By taking the medication regularly at the same time each day, you ensure that it works properly. If you forget to take a dose, take it as soon as you remember, provided it is on the same day. Then, resume your normal dosing schedule.
If an entire day is missed, do not double the next dose. Instead, continue with your normal dosing schedule and inform your healthcare provider, especially if you frequently miss doses. Skipping doses may reduce the protective effect against stroke or clot formation.
Long-Term Side Effects of Eliquis and Kidney Health
Long-term use of anticoagulants like Eliquis may carry a slight risk of ongoing blood loss, which can lead to anemia over time. To keep an eye on this, your doctor may periodically check your bloodwork to ensure your hemoglobin levels stay within a healthy range.
Although rare cases of sudden liver injury have been reported, large-scale studies haven’t shown a clear increase in liver risk with Eliquis. Still, your doctor might decide to monitor your liver function with routine blood tests as a precaution.
There is no evidence that Eliquis directly worsens kidney function; however, impaired renal clearance can heighten the risk of adverse effects if not monitored properly. Regular renal function tests are advised, especially in elderly patients and those with pre-existing kidney disease.
Special Populations: Renal Dosing in Dialysis, Elderly, and Frail Patients
For those on dialysis, a reduced dose of Eliquis may be appropriate for patients who are older or have a lower body weight. Elderly and frail patients are at an increased risk of falls, which can lead to internal bleeding while on Eliquis.
In these cases, clinicians often individualize dosing based on a combination of renal function, frailty, and bleeding risk, rather than relying solely on fixed criteria. Apixaban is the only DOAC with data supporting its use in dialysis patients, although it remains an off-label practice.
Monitoring Kidney Function While on Eliquis
Patients taking Eliquis should monitor for side effects, which include signs or symptoms of bleeding and bruising. A sudden increase in side effects could indicate accumulation of Eliquis, particularly in those with compromised kidney function.
While routine coagulation monitoring is unnecessary with Eliquis, periodic laboratory tests, such as a complete blood count (CBC) and kidney function (e.g., serum creatinine, eGFR), should be checked before initiation and at least annually, or more frequently in high-risk patients.
Additional monitoring may be warranted for high-risk populations, including those on concomitant nephrotoxic medications, those with fluctuating renal status, or elderly patients with borderline kidney function.
Articles you may also be interested in
Alternatives to Eliquis in Severe Kidney Disease
In patients with advanced kidney disease (CrCl < 15 mL/min) or those on dialysis, warfarin is traditionally used because it can be monitored closely with the INR and has a well-understood dosing range. However, recent studies have explored low-dose apixaban as a possible alternative due to its lower renal clearance compared to other DOACs. Other DOACs like rivaroxaban or dabigatran are generally avoided in severe renal impairment due to their higher dependence on kidney elimination.
Final Thoughts: Getting Eliquis Renal Dosing Right
Eliquis offers a predictable and convenient option for anticoagulation, even in patients with mild-to-moderate kidney impairment. Its lower renal clearance compared to other direct oral anticoagulants makes it a preferred choice in many cases; however, careful patient selection and dose adjustment remain critical, especially in those with multiple risk factors.
For patients with severe kidney disease or those on dialysis, treatment decisions should be individualized, weighing the available evidence, bleeding risk, and alternative options. Ongoing monitoring of kidney function, hemoglobin levels, and bleeding symptoms helps ensure the long-term safety and effectiveness of the treatment.
Frequently Asked Questions
